arrow
Return

Co-vulnerabilities of inhibiting carbonic anhydrase IX in ferroptosis-mediated tumor cell death

delete2023-11-30
delete3
delete
OA
AI
P
Paul C. McDonald
S
Shoukat Dedhar *
DOI:10.3389/fmolb.2023.1327310delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
The tumour-associated carbonic anhydrases (CA) IX and XII are upregulated by cancer cells to combat cellular and metabolic stress imparted by hypoxia and acidosis in solid tumours. Owing to its tumour-specific expression and function, CAIX is an attractive therapeutic target and this has driven intense efforts to develop pharmacologic agents to target its activity, including small molecule inhibitors. Many studies in multiple solid tumour models have demonstrated that targeting CAIX activity with the selective CAIX/XII inhibitor, SLC-0111, results in anti-tumour efficacy, particularly when used in combination with chemotherapy or immune checkpoint blockade, and has now advanced to the clinic. However, it has been observed that sustainability and durability of CAIX inhibition, even in combination with chemotherapy agents, is limited by the occurrence of adaptive resistance, resulting in tumour recurrence. Importantly, the data from these models demonstrates that CAIX inhibition may sensitize tumour cells to cytotoxic drugs and evidence now points to ferroptosis, an iron-dependent form of regulated cell death (RCD) that results from accumulation of toxic levels of phospholipid peroxidation as a major mechanism involved in CAIX-mediated sensitization to cancer therapy. In this mini-review, we discuss recent advances demonstrating the mechanistic role CAIX plays in sensitizing cancer cells to ferroptosis.
Keywords:
hypoxia
carbonic anhydrase IX
cytotoxicity
metabolism
ferroptosis
tumour microenvironment
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Frontiers in Molecular Biosciences cover
Frontiers in Molecular Biosciences
IF:
4
Papers:
6.0K
Citations:
2.0W

Organization

U
University of British Columbia
Scholars:
6.9W
Papers: 6.1W
Citations: 8.6W